Portal de Periódicos da CAPES

Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study

2023; Elsevier BV; Volume: 8; Issue: 10 Linguagem: Inglês

10.1016/s2468-1253(23)00197-8

2468-1253

Devin Razavi‐Shearer, Ivane Gamkrelidze, Calvin Q. Pan, Jidong Jia, Thomas Berg, Richard T. Gray, Young‐Suk Lim, Chien‐Jen Chen, Ponsiano Ocama, Hailemichael Desalegn, Zaigham Abbas, Ayat R. Abdallah, Alessio Aghemo, Sabohat Ahmadbekova, Sang Hoon Ahn, Inka Aho, Ulus Salih Akarca, Nasser Al Masri, Abduljaleel Alalwan, Seyed Moayed Alavian, Said A. Al‐Busafi, Soo Aleman, Faleh Alfaleh, Abdullah Alghamdi, Waleed Al–Hamoudi, Abdulrahman Aljumah, Khalid Al‐Naamani, Ahmad Al‐Rifai, Yousif Mohamed AlSerkal, Ibrahim Altraif, Amarsanaa Jazag, Motswedi Anderson, Monique Andersson, Paige A. Armstrong, Tarik Asselah, Kostas Athanasakis, Oidov Baatarkhuu, Ziv Ben‐Ari, Aïcha Bensalem, Fernando Bessone, Mia J. Biondi, Abdul Rahman Bizri, Sarah Blach, Wornei Silva Miranda Braga, Carlos Eduardo Brandão‐Mello, Carol Brosgart, Kimberly Brown, Robert S. Brown, Philip Bruggmann, Maurizia Rossana Brunetto, Marı́a Buti, Joaquín Cabezas, Teresa Casanovas, Chungman Chae, Henry Lik‐Yuen Chan, Hugo Cheinquer, Pei‐Jer Chen, Kent Jason Cheng, Myeong-Eun Cheon, Cheng‐Hung Chien, Gourdas Choudhuri, Peer Brehm Christensen, Wan‐Long Chuang, Vladimir Chulanov, Laura Cisneros, Carla S. Coffin, F. Contreras, Nicola Coppola, Markus Cornberg, Benjamin C Cowie, Matthew Cramp, Antonio Craxı̀, Javier Crespo, Fuqiang Cui, Chris Cunningham, Olav Dalgård, Robert J. de Knegt, Victor de Lédinghen, Gregory J. Dore, Sylvia Dražilová, Ann‐Sofi Duberg, Steve S Egeonu, Mohammed Elbadri, Mohamed El‐Kassas, Manal H. El‐Sayed, Chris Estes, Ohad Etzion, Elmoubasher Farag, Laurent Ferradini, Paulo Roberto Abrão Ferreira, Robert Flisiak, Xavier Forns, Soňa Fraňková, James Fung, Edward Gane, Virginia Garcia, Javier García‐Samaniego, Manik Gemilyan, Jordan Genov, Liliana Gheorghe, Pierre M. Gholam, Robert G. Gish, Pouya Goleij, Magnús Gottfreðsson, Jason Grebely, Michael Gschwantler, Nanelin Alice Guingane, Behzad Hajarizadeh, Saeed Hamid, Waseem Hamoudi, Aaron M. Harris, Irsan Hasan, Angelos Hatzakis, Margaret Hellard, Julian Hercun, Javier Hernández, Ivana Hockicková, Yao‐Chun Hsu, Ching‐Chih Hu, Petr Husa, Martin Janíčko, Naveed Z. Janjua, Peter Jarčuška, Jerzy Jaroszewicz, Deian Jelev, Agita Jēruma, Asgeir Johannessen, Martin Kåberg, Kelly Kaita, Kulpash Kaliaskarova, Jia‐Horng Kao, Angela Kelly‐Hanku, Faryal Khamis, Aamir Ghafoor Khan, Omer Kheir, Ibtissam Khoudri, Loreta A. Kondili, Aliya Konysbekova, Pavol Kristián, Jisoo A. Kwon, Martin Lagging, Wim Laleman, Pietro Lampertico, Daniel Lavanchy, Pablo Lázaro, Jeffrey V. Lazarus, Alice Lee, Mei‐Hsuan Lee, Valentina Liakina, Boris Lukšić, Reza Malekzadeh, Abraham O. Malu, Rui Tato Marinho, Maria Cássia Mendes-Corrêa, Shahin Merat, Berhane Redae Meshesha, Håvard Midgard, Rosmawati Mohamed, Jacques Mokhbat, Ellen Mooneyhan, Christophe Moreno, Laure Mortgat, Beat Müllhaupt, Erkin Musabaev, Gaëtan Muyldermans, Marcelo Contardo Moscoso Naveira, Francesco Negro, Alexander Nersesov, Van Thi Thuy Nguyen, Qing Ning, Richard Njouom, R. Ntagirabiri, Zuridin Nurmatov, Stephen Oguche, Casimir Omuemu, Janus P. Ong, Ohene Opare‐Sem, Necati Örmecı, Mauricio Orrego, Carla Osiowy, George Papatheodoridis, Markus Peck‐Radosavljevic, Mário G. Pessôa, T.T.K. Pham, Richard Odame Phillips, Nikolay Pimenov, Loreley Pincay-Rodríguez, Dijana Plaseska‐Karanfilska, Cora Pop, Hossein Poustchi, Nishi Prabdial‐Sing, Huma Qureshi, Alnoor Ramji, Henna Rautiainen, Kathryn Razavi‐Shearer, William Remak, Sofia Ribeiro, Ezequiel Ridruejo, Cielo Ríos, Marcia Robalino, Lewis R. Roberts, Stuart K. Roberts, Manuel Rodríguez, Dominique Roulot, John Rwegasha, Stephen Ryder, Shakhlo Sadirova, Umar Saeed, Rifaat Safadi, Olga Sagalova, Sanaa Said, Riina Salupere, Faisal M. Sanai, J.F. Sánchez-Ávila, Vivek A. Saraswat, Narina Sargsyants, Christoph Sarrazin, Gulya Sarybayeva, Ivan Schréter, Carole Seguin‐Devaux, Wai‐Kay Seto, Samir Shah, Ala I. Sharara, Mahdi Sheikh, Daniel Shouval, William Sievert, Kaarlo Simojoki, Marieta Simonova, Dong Hyun Sinn, Mark Sonderup, Milan J. Sonneveld, C. Wendy Spearman, Jan Šperl, Rudolf Stauber, Catherine Stedman, Vana Sypsa, Frank Tacke, Soek-Siam Tan, Junko Tanaka, Tammo Lambert Tergast, Norah A. Terrault, Alexander J. Thompson, Peyton Thompson, Ieva Tolmane, Krzysztof Tomasiewicz, Tak-Yin Tsang, Benjamin Uzochukwu, Berend Van Welzen, Thomas Vanwolleghem, Adriana Vince, Alexis Voeller, Yasir Waheed, Imam Waked, Jack Wallace, Cong Wang, Nina Weis, Grace Lai‐Hung Wong, Vincent Wai‐Sun Wong, Jaw‐Ching Wu, César Yaghi, Kakharman Yesmembetov, Terry Cheuk‐Fung Yip, Ayman Yosry, Ming‐Lung Yu, M.-F. Yuen, Cihan Yurdaydìn, Stefan Zeuzem, Eli Zuckerman, Homie Razavi,

Liver Disease Diagnosis and Treatment

Background The 2016 World Health Assembly endorsed the elimination of hepatitis B virus (HBV) infection as a public health threat by 2030; existing therapies and prophylaxis measures make such elimination feasible, even in the absence of a virological cure. We aimed to estimate the national, regional, and global prevalence of HBV in the general population and among children aged 5 years and younger, as well as the rates of diagnosis, treatment, prophylaxis, and the future burden globally. Methods In this modelling study, we used a Delphi process with data from literature reviews and interviews with country experts to quantify the prevalence, diagnosis, treatment, and prevention measures for HBV infection. The PRoGReSs Model, a dynamic Markov model, was used to estimate the country, regional, and global prevalence of HBV infection in 2022, and the effects of treatment and prevention on disease burden. The future incidence of morbidity and mortality in the absence of additional interventions was also estimated at the global level. Findings We developed models for 170 countries which resulted in an estimated global prevalence of HBV infection in 2022 of 3·2% (95% uncertainty interval 2·7–4·0), corresponding to 257·5 million (216·6–316·4) individuals positive for HBsAg. Of these individuals, 36·0 million were diagnosed, and only 6·8 million of the estimated 83·3 million eligible for treatment were on treatment. The prevalence among children aged 5 years or younger was estimated to be 0·7% (0·6–1·0), corresponding to 5·6 million (4·5–7·8) children with HBV infection. Based on the most recent data, 85% of infants received three-dose HBV vaccination before 1 year of age, 46% had received a timely birth dose of vaccine, and 14% received hepatitis B immunoglobulin along with the full vaccination regimen. 3% of mothers with a high HBV viral load received antiviral treatment to reduce mother-to-child transmission. Interpretation As 2030 approaches, the elimination targets remain out of reach for many countries under the current frameworks. Although prevention measures have had the most success, there is a need to increase these efforts and to increase diagnosis and treatment to work towards the elimination goals. Funding John C Martin Foundation, Gilead Sciences, and EndHep2030.